About: Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
Creator	Blasi, Francesco Aliberti, Stefano Gramegna, Andrea Radovanovic, Dejan Rupp, Jan Sotgiu, Giovanni Terraneo, Silvia Restrepo, Marcos Reyes, Luis Castillo, Del Francesca, Marta González, Juan Pasquale, Di
source	Medline; PMC
abstract	BACKGROUND: The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. METHODS: We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. RESULTS: At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non–community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001). CONCLUSIONS: Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.
has issue date	2018-08-23(xsd:dateTime)
bibo:doi	10.1093/cid/ciy723
bibo:pmid	31222287
has license	green-oa
sha1sum (hex)	6ad8104b50986065ba9b7cbac8fec261b8a97062
schema:url	https://doi.org/10.1093/cid/ciy723
resource representing a document's title	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
has PubMed Central identifier	PMC6481991
has PubMed identifier	31222287
schema:publication	Clinical Infectious Diseases
resource representing a document's body	covid:6ad8104b50986065ba9b7cbac8fec261b8a97062#body_text
is schema:about of	named entity 'INFECTIOUS DISEASES' named entity 'CAP' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'immunocompromised' named entity 'Patients' named entity 'Etiology' named entity '80%' named entity 'EVALUATED' named entity 'PREVALENCE' named entity 'CLINICAL' named entity 'CORRECT' named entity 'IMMUNOCOMPROMISED PATIENTS' named entity 'CID' named entity 'COMING' named entity 'RISK FACTORS' named entity 'BACKGROUND' named entity 'CHARACTERISTICS' named entity 'IMMUNOCOMPROMISED PATIENTS' named entity 'PATIENTS' named entity 'PNEUMONIA' named entity 'MANAGEMENT' named entity 'PREVALENCE' named entity 'ETIOLOGY' named entity '2018' named entity 'COMMUNITY' covid:arg/6ad8104b50986065ba9b7cbac8fec261b8a97062 named entity 'pneumonia' named entity 'evaluated' named entity 'risk factors' named entity 'immunocompromised patients' named entity 'risk factors' named entity 'anaerobes' named entity 'immunocompromise' named entity 'bacteremia' named entity 'Streptococcus pneumoniae' named entity 'IBM' named entity 'North America' named entity 'S. aureus' named entity 'pulmonary infiltrate' named entity 'antibiotic resistance' named entity 'Immunocompromise' named entity 'microbiology' named entity 'steroids' named entity 'microbes' named entity 'Microbiological' named entity 'solid tumor' named entity 'risk factors' named entity 'immunocompromised state' named entity 'CD4' named entity 'risk factor' named entity 'neutropenia' named entity 'severe pneumonia' named entity 'steroids' named entity 'neutropenia' named entity 'immunocompromised patients' named entity 'pathogens' named entity 'respiratory syncytial virus' named entity 'Mycoplasma pneumoniae' named entity 'risk factor' named entity 'immunocompromise' named entity 'Asia and Africa' named entity 'mycobacterial' named entity 'aplastic anemia' named entity 'steroids' named entity 'pathogens' named entity 'solid organ transplant' named entity 'purulent' named entity 'Aspergillus fumigatus' named entity 'immunocompromised'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software